Amit Singal, MD, UT Southwestern Medical Center

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

October 1st 2021

Takeaways from a discussion on treatment advances in hepatocellular carcinoma.

Biomarkers to Guide HCC Treatment Decisions

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

October 1st 2021

Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.

Second-Line Treatment Approaches for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 24th 2021

An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.

The COSMIC-312 Study in Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 24th 2021

Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.

HCC: IO in Liver Transplant Recipients

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 17th 2021

A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.

The LEGACY Study in HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 17th 2021

Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.

Selecting First-Line Therapy for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 10th 2021

An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.

Frontline IO for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 10th 2021

Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.

Systemic Treatment Advances for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 3rd 2021

Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.

Scoring/Classifying Patients With Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 3rd 2021

Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.

Adjuvant Treatment Advances in Operable HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 27th 2021

Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.

Hepatic Arterial Infusion Chemotherapy for HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 27th 2021

Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.

Neoadjuvant Therapy to Downstage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 20th 2021

Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.

Advances in Locoregional Therapy for Early Stage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 20th 2021

University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.

Current Role of Locoregional Therapy for Early Stage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 13th 2021

Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.

Diagnosing Early-Stage HCC via Biopsy

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 13th 2021

A debate regarding the current role of biopsy to confirm a diagnosis of early-stage hepatocellular carcinoma.

Diagnostic Testing for Early Stage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 6th 2021

The rationale for diagnostic imaging to evaluate and diagnose early stage hepatocellular carcinoma.

Screening for Early Stage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 6th 2021

A brief overview of criteria and tools used to assess, and risk stratify patients with early stage hepatocellular carcinoma.

Future Directions of HCC

Amit Singal, MD, UT Southwestern Medical Center;Masatoshi Kudo, MD, PhD, Kindai University;Stephan L. Chan, MD, The Chinese University of Hong Kong

April 14th 2021

Stephen L. Chan, MD; Masatoshi Kudo, MD, PhD; and Amit Singal, MD, discuss the future treatment landscape for the management of HCC (hepatocellular carcinoma).

Using AFP as a Biomarker in HCC

Amit Singal, MD, UT Southwestern Medical Center;Masatoshi Kudo, MD, PhD, Kindai University;Stephan L. Chan, MD, The Chinese University of Hong Kong

April 14th 2021

Stephen L. Chan, MD, comments on the use of AFP as a predictive biomarker in HCC (hepatocellular carcinoma) and the current use of ramucirumab.

Sequencing With Anti-PD-1 Antibodies in HCC

Amit Singal, MD, UT Southwestern Medical Center;Masatoshi Kudo, MD, PhD, Kindai University;Stephan L. Chan, MD, The Chinese University of Hong Kong

April 14th 2021

Amit Singal, MD; Masatoshi Kudo, MD, PhD; and Stephen L. Chan, MD, share their personal approaches to sequencing with an anti-PD-1 antibody after first-line atezolizumab-bevacizumab in HCC (hepatocellular carcinoma).

Challenges of Sequencing and Biomarkers in Hepatocellular Carcinoma

Richard S. Finn, MD, UCLA Health;Daniel H. Ahn, DO, Mayo Clinic;Laura M. Kulik, MD, Northwestern;Daneng Li, MD, City of Hope;Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine;Amit Singal, MD, UT Southwestern Medical Center

April 8th 2021

Experts provide insight into the challenges of sequencing and biomarkers when treating advanced HCC.

Role of Single Agent IO in Hepatocellular Carcinoma Frontline Therapies

Richard S. Finn, MD, UCLA Health;Daniel H. Ahn, DO, Mayo Clinic;Laura M. Kulik, MD, Northwestern;Daneng Li, MD, City of Hope;Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine;Amit Singal, MD, UT Southwestern Medical Center

April 8th 2021

A summary of ongoing clinical data that explore the use of frontline single agent immunotherapy in advanced HCC.

CELESTIAL and RESORCE Trials in HCC

Amit Singal, MD, UT Southwestern Medical Center;Masatoshi Kudo, MD, PhD, Kindai University;Stephan L. Chan, MD, The Chinese University of Hong Kong

April 7th 2021

Amit Singal, MD, comments on the use of cabozantinib in patients with Child-Pugh A and Child-Pugh B disease as well as regorafenib in advanced stage HCC (hepatocellular carcinoma).

Role of VEGF TKIs for Second-Line Therapy in HCC

Amit Singal, MD, UT Southwestern Medical Center;Masatoshi Kudo, MD, PhD, Kindai University;Stephan L. Chan, MD, The Chinese University of Hong Kong

April 7th 2021

Considerations for selecting a VEGF TKI (tyrosine kinase inhibitor) in the second-line setting for the management of HCC (hepatocellular carcinoma).

Approaching Second-Line Therapy in HCC

Amit Singal, MD, UT Southwestern Medical Center;Masatoshi Kudo, MD, PhD, Kindai University;Stephan L. Chan, MD, The Chinese University of Hong Kong

March 31st 2021

Amit Singal, MD, shares his thoughts on approaching second-line therapy for HCC (hepatocellular carcinoma) after first-line atezolizumab-bevacizumab as well as options for patients with Child-Pugh B disease who are ineligible for frontline atezolizumab-bevacizumab.

KEYNOTE-240 and HIMALAYA Trials in Advanced HCC

Amit Singal, MD, UT Southwestern Medical Center;Masatoshi Kudo, MD, PhD, Kindai University;Stephan L. Chan, MD, The Chinese University of Hong Kong

March 31st 2021

A review of currently available ongoing data for unresectable HCC (hepatocellular carcinoma), including data from the HIMALAYA trial.

Frontline Trials for Unresectable HCC

Amit Singal, MD, UT Southwestern Medical Center;Masatoshi Kudo, MD, PhD, Kindai University;Stephan L. Chan, MD, The Chinese University of Hong Kong

March 25th 2021

Amit Singal, MD, MS, and Stephen L. Chan, MD, review the IMbrave150, LEAP-002, and CheckMate 9DW trials for unresectable hepatocellular carcinoma.

TACE-3 and CheckMate 74W Trials for BCLC stage B or stage C HCC

Amit Singal, MD, UT Southwestern Medical Center;Masatoshi Kudo, MD, PhD, Kindai University;Stephan L. Chan, MD, The Chinese University of Hong Kong

March 25th 2021

Stephen L. Chan, MD, reviews data from key trials of emerging combinations of TACE (transarterial chemoembolization), plus systemic therapies for BCLC (Barcelona Clinic Liver Cancer) stage B or C hepatocellular carcinoma.

Emerging Combinations of TACE for BCLC Stage B/C HCC

Amit Singal, MD, UT Southwestern Medical Center;Masatoshi Kudo, MD, PhD, Kindai University;Stephan L. Chan, MD, The Chinese University of Hong Kong

March 17th 2021

Masatoshi Kudo, MD, PhD, reviews data from the LEAP-012 and TACTICS trials for intermediate stage hepatocellular carcinoma.

Amit Singal, MD, UT Southwestern Medical Center

Articles

Latest Updated Articles

Latest Conference Coverage